Literature DB >> 15464682

Risk of adverse events with fibrates.

Alawi A Alsheikh-Ali1, Jeffrey T Kuvin, Richard H Karas.   

Abstract

An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15464682     DOI： 10.1016/j.amjcard.2004.06.033

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  23 in total

1.  Use of fibrates in the United States and Canada.

Authors:  Cynthia A Jackevicius; Jack V Tu; Joseph S Ross; Dennis T Ko; Daniel Carreon; Harlan M Krumholz
Journal:  JAMA       Date:  2011-03-23       Impact factor: 56.272

Review 2.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?

Authors:  Willibald Hochholzer; Robert P Giugliano
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

4.  Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin.

Authors:  Weibin Qian; Xinrui Cai; Xinying Zhang; Yingying Wang; Qiuhai Qian; Junichi Hasegawa
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

5.  Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.

Authors:  M Ledl; J Hohenecker; C Francesconi; I Roots; M F Bauer; M Roden
Journal:  Diabetologia       Date:  2005-08-17       Impact factor: 10.122

Review 6.  Lipid-lowering drugs.

Authors:  K Pahan
Journal:  Cell Mol Life Sci       Date:  2006-05       Impact factor: 9.261

Review 7.  Toxic myopathies.

Authors:  Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 8.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

Review 9.  Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Authors:  Eliot A Brinton
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 10.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Authors:  Venkata M Alla; Vrinda Agrawal; Andrew DeNazareth; Syed Mohiuddin; Sudha Ravilla; Marc Rendell
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.